PMID:22955915

Citation	Xu-Monette, ZY, Wu, L, Visco, C, Tai, YC, Tzankov, A, Liu, WM, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Zhao, XF, Choi, WW, Zhao, X, van Krieken, JH, Huang, Q, Huh, J, Ai, W, Ponzoni, M, Ferreri, AJ, Zhou, F, Kahl, BS, Winter, JN, Xu, W, Li, J, Go, RS, Li, Y, Piris, MA, Møller, MB, Miranda, RN, Abruzzo, LV, Medeiros, LJ and Young, KH (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 120:3986-96
Abstract	TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In the present study of a large cohort of DLBCL patients treated with rituximab plus CHOP (R-CHOP), we show that those with TP53 mutations had worse overall and progression-free survival compared with those without. Unlike earlier studies of patients treated with CHOP, TP53 mutation has predictive value for R-CHOP-treated patients with either the germinal center B-cell or activated B-cell DLBCL subtypes. Furthermore, we identified the loop-sheet-helix and L3 motifs in the DNA-binding domain to be the most critical structures for maintaining p53 function. In contrast, TP53 deletion and loss of heterozygosity did not confer worse survival. If gene mutation data are not available, immunohistochemical analysis showing > 50% cells expressing p53 protein is a useful surrogate and was able to stratify patients with significantly different prognoses. We conclude that assessment of TP53 mutation status is important for stratifying R-CHOP-treated patients into distinct prognostic subsets and has significant value in the design of future therapeutic strategies.
Links	PubMed PMC3496956 Online version:10.1182/blood-2012-05-433334
Keywords	Adult; Aged; Alleles; Antibodies, Monoclonal, Murine-Derived/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cohort Studies; Computational Biology; Cyclophosphamide/therapeutic use; Doxorubicin/therapeutic use; Exons; Female; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Loss of Heterozygosity; Lymphoma, Large B-Cell, Diffuse/drug therapy; Lymphoma, Large B-Cell, Diffuse/genetics; Lymphoma, Large B-Cell, Diffuse/mortality; Male; Middle Aged; Mutation; Mutation Rate; Mutation, Missense; Neoplasm Staging; Prednisone/therapeutic use; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53/genetics; Tumor Suppressor Protein p53/metabolism; Vincristine/therapeutic use
edit table

Annotations

Gene product	Qualifier	GO Term	Evidence Code	with/from	Aspect	Extension	Notes	Status
HUMAN:P53		GO:0030330: DNA damage response, signal transduction by p53 class mediator	ECO:0000315:		P		Figure 1 shows that a mutation in the p53 results in mutations in the DNA-binding domain, in DLBCL (Diffuse large B-cell lymphoma) patients Figure 2 shows that a mutation of the p53 results in poor survival rates for those with DLBCL	complete CACAO 8005

References

See Help:References for how to manage references in GONUTS.